Marisa Wexler, MS, senior science writer —

Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…

Ultomiris (ravulizumab) has been approved by the European Commission to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4). “Effective NMOSD management hinges on reducing relapses – even a single relapse may cause irreversible disabilities leaving patients unable to move, speak…

Antibodies against aquaporin-4 (AQP4) are detectable in the blood several years before symptoms occur in most people with neuromyelitis optica spectrum disorder (NMOSD), according to a U.S. study. Tammy Smith, MD, PhD, of the University of Utah, presented the findings at the recent American Academy of Neurology (AAN) annual…

Experts in Germany have published recommendations to help clinicians diagnose neuromyelitis optica spectrum disorder (NMOSD) and distinguish it from other disorders with similar symptoms. The guidelines were detailed in “Update on the diagnosis and treatment of [neuromyelitis] optica spectrum disorders (NMOSD) – revised recommendations of the…

Living with neuromyelitis optica spectrum disorder (NMOSD) and resulting disability can make it hard to find and keep employment, according to a small U.S. study that nonetheless involved patients from more than a dozen states. Group discussions with 20 people with the rare autoimmune disease — of varying races…

A European Medicines Agency (EMA) committee has recommended that Ultomiris (ravulizumab) be approved to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), will now be reviewed by the European…

Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…

The annual prevalence of neuromyelitis optica spectrum disorder (NMOSD) in the U.S. is considerably higher than previously estimated, affecting about nine out of every 100,000 people, according to a study that analyzed 2021 electronic health records. The data also showed that the disease is more than twice as common…

Levels of double-stranded DNA — dubbed dsDNA — are elevated in the fluid around the brain and spinal cord of people with severe neuromyelitis optica spectrum disorder (NMOSD), a small study suggests. These levels, which indicate cellular damage, may trigger more inflammation in NMOSD patients, potentially contributing to the…

The CAR T-cell therapy CT103A appears safe generally and may ease disability and improve the quality of life in adults with relapsed or refractory neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4), according to data from a small Phase 1 clinical trial. “In this…